Hamza Ibrahim, 8, from Adelaide, was just like any other schoolboy, but earlier this year he started experiencing headaches, nausea and general clumsiness.
Jordan Hansford, MD, discusses the phase 2 FIREFLY-1 trial, which is investigating the pan-RAF inhibitor tovorafenib (DAY101) in children and young adults with low-grade glioma.